Product Datasheet

(R)-NX-2127


Catalog No. **BP-00111** · CAS **3024312-52-2** · Form **free base** · Physical state **solid** · Version **1.0** · Revision **2026-11-12**

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target	Research area
Drug Isomer; PROTACs; Molecular Glues; Btk; IKZF Family; Interleukin Related	**Cancer**

Molecular formula	$C_{39}H_{45}N_9O_5$
Molecular weight	**719.8319**

STRUCTURE



DESCRIPTION

(R)-NX-2127 (compound 28) is an orally active Bruton's Tyrosine Kinase (Btk) degrader. (R)-NX-2127 degrades IKZF1 and IKZF3 by molecular glue interactions with the cereblon E3 ubiquitin ligase complex .

BIOLOGICAL ACTIVITY

(R)-Zelebrudomide ((R)-NX-2127) is an isomer of Zelebrudomide (HY-153220). Zelebrudomide (NX-2127) degrades wild-type BTK in TMD8 cells with a DC50 of 4.5 nM; it also degrades the BTKC481S mutant with a DC50 of 31 nM (R)-Zelebrudomide is an isomer of Zelebrudomide. Zelebrudomide (0.001-100 nM; 1-24 h) degrades IKZF1 (DC50 = 57 nM) and IKZF3 (DC50 = 36 nM) in primary human T cells, and induces IL-2 secretion in TCR-activated primary human T cells

SOLUBILITY

Soluble in DMSO

REFERENCES

[1]. Robbins DW, et al. Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton's Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies. J Med Chem. 2024 Feb 22;67(4):2321-2336.